One notable difference between use of FBS or PL was that in OM-PL RUNX2 expression was more significantly covariant with other biomarker genes, namely BGN, CADM1, COL1A1 and ELN at two weeks and BGN, COL1A1 and ELN at one week (Table 4). This evidence concerns the gene BGN and ocular melanoma.